Myelofibrosis Therapeutics Market Size
The global myelofibrosis therapeutics market reached US$ 3.24 billion in 2025 and is expected to reach US$ 7.63 billion by 2033, growing at a CAGR of 7.6% during the forecast period 2026-2033.
Myelofibrosis is a rare form of blood cancer in which the scar tissue builds up in the bone marrow, as a result, the production of new blood cells becomes deficit. Myelofibrosis is related to myeloproliferative disorders, a plethora of conditions affecting bone marrow and causing abnormal blood cell production. There are two types of myelofibrosis, primary and secondary. Primary myelofibrosis occurs on its own, whereas secondary myelofibrosis occurs due to other types of bone marrow conditions such as polycythemia vera or thrombocythaemia.
The exact cause of primary myelofibrosis is unknown, but certainly caused by mutations in the hematopoietic stem cells which divide abnormally and form megakaryocytes in the bone marrow. These megakaryocytes build up in the bone marrow and trigger the cytokines which causes inflammation and buildup of fibrous tissue.
The treatment of myelofibrosis is focused on symptomatic relief mostly as the majority of the patients slowly progress to severity and do not show symptoms in the beginning. The common treatment modalities are blood transfusions, targeted drug therapy, chemotherapy, surgery, bone marrow transplantation, palliative care, etc. Several targeted therapies have been approved in recent times which are revolutionizing the myelofibrosis therapeutics.
Myelofibrosis Therapeutics Market Scope
| Metrics | Details |
| CAGR | 7.6% |
| Market Size | 2023-2033 |
| Market Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Type, Therapy Type, Gender, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Myelofibrosis Therapeutics Market Dynamics: Drivers
The myelofibrosis therapeutics market is primarily driven by the increasing adoption of targeted therapies, particularly JAK inhibitors, which have significantly improved symptom management and patient outcomes. Growing research and development investments, along with a strong clinical pipeline of novel drug classes such as BET inhibitors, telomerase inhibitors, and combination therapies, are accelerating innovation in this space. Additionally, the rising focus on precision medicine and biomarker-based treatment approaches is enabling more personalized and effective therapies. Improvements in stem cell transplantation techniques and supportive regulatory incentives for orphan drugs are further contributing to market expansion by enhancing treatment accessibility and encouraging pharmaceutical innovation.
Despite these positive trends, the market faces several restraints that limit its full growth potential. High treatment costs, especially for advanced biologics and targeted therapies, remain a significant barrier, particularly in low- and middle-income regions. Adverse effects associated with existing treatments, including anemia, infections, and thrombocytopenia, can impact patient adherence and outcomes. Additionally, the rarity and complexity of myelofibrosis lead to delayed diagnosis and limited patient pools, which restrict large-scale clinical trials and slow drug development. Regulatory challenges, reimbursement uncertainties, and inadequate healthcare infrastructure in developing regions further hinder widespread adoption of therapies.
On the opportunity side, the market is witnessing strong potential through the integration of digital health technologies, real-world data, and artificial intelligence to improve disease monitoring and treatment planning. There is a significant unmet need for effective therapies in high-risk and refractory patient populations, which is driving the development of next-generation treatments, including gene and cell-based therapies. Expansion in emerging markets, supported by improving diagnostic capabilities and healthcare investments, is also expected to create new growth avenues. Moreover, increasing collaborations between pharmaceutical companies, research institutions, and biotech firms are accelerating the development of innovative therapies, positioning the market for sustained long-term growth.
| S.No | Drug Candidate | Manufactuter | Clinical Trial Phase | Estimated Trial Completion Date | Estimated Market Entry |
| 1 | Pelabresib | MorphoSys AG | Phase 3 | 2027 | 2028 |
| 2 | Pacritinib | CTI BIOPHARMA CORP. | Phase 3 | 2025 | Approved in the U.S. |
| 3 | Selinexor | Karyopharm Therapeutics Inc. | Phase 3 | 2028 | 2029 |
Note: Only the drugs under phase 3 were considered in leu with our forecast period. Several drugs are currently in the early phases of clinical trials, which are anticipated to enter the market in the next decade. Also, the market entry year is estimated based on the approval timeline for already marketed drugs.
Moreover, the rising prevalence of myelofibrosis and rising funding for research and development activities are expected to drive market growth in the forecast period.
Restraints
Factors such as limited awareness of the disease to patients and the high cost of treatment are expected to restrain the market growth.
Myelofibrosis Therapeutics Market Segment Analysis
The global myelofibrosis therapeutics market is segmented based on type, therapy type, gender, end user, and region.
The targeted therapies in the treatment type segment accounted for approximately 41.30% of the global myelofibrosis therapeutics market share
Although the etiology of myelofibrosis is not known, a strong emphasis was made on the Janus kinase (JAK) enzyme, whose mutation is the major cause of myelofibrosis. Approximately 50% to 60% of myelofibrosis patients have the JAK1/JAK2 mutation which leads to abnormal blood cell production. Targeting these mutant components which ought to cause myelofibrosis is the main idea behind developing targeted therapy. As of now, regulatory bodies such as the FDA or EU Commission have only approved targeted therapy drugs against myelofibrosis which have gained a lot of importance.
Other therapies such as blood transfusion, androgen therapy, hydroxyurea, and immunomodulators focus on alleviating the symptoms but not the cure. The only cure available for myelofibrosis is stem cell transplantation, but only a limited number of the population with myelofibrosis are eligible who are at high risk and also healthy. For instance, an article published in Elsevier on November 16, 2023 states that hematopoietic stem cell transplantation procedures are rising, but the morbidities associated with it limit the target population. Only the elderly population presents with severe symptoms and severe bone marrow fibrosis and managing them through transplantation procedures poses a great challenge.
Since the majority of the patients with myelofibrosis have mild to moderate severity managing them with targeted therapies has become a gold standard approach. For instance, on February 19, 2024, an article published in the Journal of American Cancer Society stated that the current standard of care treatment for myelofibrosis is the targeted therapy drugs that inhibit JAK/STAT signaling pathways. Ruxolitinib, and fedratinib which are JAK inhibitors have revolutionized the myelofibrosis treatment.
Moreover, in 2023, momelotinib which is another targeted therapy was approved by the FDA and EU to use in myelofibrosis patients with anemia. Likewise, several are in clinical trials anticipated to be launched in this decade. This growing focus on targeted therapies is a major factor contributing to the greater market share for targeted therapies.
The sales of these approved targeted therapies have been rising since their launch and have attained lucrative growth till now. For instance, As per dataM analysis, the revolutionary drug Jakafi (Ruxolitinib) sales were growing at a compound annual growth rate of 11.4% and generated a whopping $2.5 billion in revenue in 2023.
Fig 1: Sales growth projection of Jakafi (Ruxolitinib)
As per DataM analysis, the market value of all the approved targeted therapies for myelofibrosis is approximately $2.8 billion.
Fig:2 Sales value (in USD million) of approved targeted therapies for myelofibrosis in 2023
Myelofibrosis Therapeutics Market Geographical Analysis
North America is expected to dominate the market with a 45.30% share in the Global myelofibrosis therapeutics Market
North America is expected to dominate the market due to its well-equipped healthcare facilities and cancer therapeutics centers. The manufacturers of targeted therapies generate the majority of the revenue from the region which is a strong contributing factor for the region’s highest market share. Moreover, the region is well known for providing better access to healthcare services by helping patients with financial coverage. Several government and non-profit organizations in the U.S. provide support for patients who cannot afford the treatment.
For instance, The Leukemia & Lymphoma Society (LLS) in the U.S. provides financial assistance to blood cancer patients including those with myelofibrosis as a part of a co-pay assistance program. The funding is provided to LLS by pharmaceutical and biotechnology companies in the U.S. The program provides financial assistance of up to $4000 per patient with myelofibrosis.
In addition, due to the region's highest expenditure on healthcare, the healthcare facilities provide a plethora of treatment services to myelofibrosis patients. Stem cell therapy which is considered to be the ultimate cure for myelofibrosis is provided by various hospitals and medical institutes across the region.
For instance, The University of Texas MD Anderson Cancer Center has the largest stem cell transplantation program in the U.S. which provides approximately 850 transplants annually in both adults and pediatrics. Likewise, several cancer institutes across the region provide top-tier treatment for myelofibrosis patients.
Moreover, the regulatory scenario in the region is robust with FDA being the governing body that stringently regulates the products and also provides support for innovative therapies. FDA also conducts expedited review programs and provides accelerated approval for absolutely necessary and breakthrough therapies.
For instance, in February 2022, the US Food and Drug Administration provided accelerated approval for Vonjo (pacritinib) to treat intermediate to high-risk myelofibrosis patients. After the approval, the drug was launched in the U.S. market and has attained approximately $60 million in sales in 2023. These are the strong contributing factors for the region’s highest market share in the myelofibrosis therapeutics market.
Recent Developments
February 2026: Rising prevalence of rare blood cancers such as myelofibrosis and increasing adoption of targeted therapies accelerated market growth across North America and Europe, where advanced hematology care infrastructure supports early diagnosis and treatment.
January 2026: Advancements in JAK inhibitor therapies, including ruxolitinib and next-generation agents, gained traction in the United States and Japan, improving symptom control and extending patient survival rates.
December 2025: Leading companies such as Incyte Corporation (United States), Novartis AG (Switzerland), Bristol Myers Squibb (United States), and GSK plc (United Kingdom) expanded their oncology portfolios with innovative myelofibrosis treatments and pipeline candidates.
November 2025: Increasing adoption of targeted therapies and combination treatment approaches across North America and Europe boosted demand, particularly for managing splenomegaly and anemia in myelofibrosis patients.
October 2025: Growing healthcare investments and improved diagnostic capabilities in Asia-Pacific, especially in China, India, and Japan, enhanced access to advanced therapeutics and supported regional market expansion.
September 2025: Regulatory approvals and ongoing clinical trials in the United States and the United Kingdom strengthened the development pipeline, including novel JAK inhibitors and disease-modifying therapies.
August 2025: Increasing R&D investments and strategic collaborations across Europe and Japan accelerated innovation in precision medicine and next-generation hematology treatments.
The market is evolving toward targeted, high-efficacy therapies, with North America leading due to strong adoption of JAK inhibitors, Europe focusing on regulatory and clinical advancements, and Asia-Pacific emerging as a high-growth region driven by improving healthcare access and rising awareness.
Myelofibrosis Therapeutics Market Competitive Landscape
The major players in the myelofibrosis therapeutics market include Daiichi Sankyo, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., AstraZeneca., Eisai Inc., Puma Biotechnology, Inc., Bristol-Myers Squibb Company., Bayer, and Eli Lilly and Company among others.
Why Purchase the Report?
- To visualize the global myelofibrosis therapeutics market segmentation based on type, therapy type, gender, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of myelofibrosis therapeutics market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global myelofibrosis therapeutics market report would provide approximately 70 tables, 64 figures, and 187 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
